Long-term efficacy of pravastatin therapy in diabetic patients undergoing complete coronary revascularization

J Atheroscler Thromb. 2010 Apr 30;17(4):350-5. doi: 10.5551/jat.1925. Epub 2010 Feb 13.

Abstract

Aim: The long-term effect of statin therapy in diabetic patients after coronary revascularization is not well established. Accordingly, we sought to determine if whether statin therapy initiated at the time of complete revascularization including percutaneous coronary intervention (PCI) and/or bypass surgery reduces total and cardiac mortality among diabetic patients.

Methods: We collected data from 1,138 consecutive patients who underwent complete revascularization (PCI and/or bypass surgery). We then compared all-cause and cardiac mortality rates in 499 patients with diabetes mellitus of whom 149 (29.9%) were treated with statin at the time of revascularization. To adjust the variables that would have been related to the decision regarding statin administration, a propensity score was computed and multivariate Cox regression was carried out.

Results: During follow-up (8.8+/-2.6 years), 103 patients died (including 43 who died of cardiac causes). The Multivariate analysis showed statin therapy to be significantly associated with reduced cardiac mortality (HR 0.39, 0.16-0.95; p=0.039), but not with all-cause mortality.

Conclusion: Statin therapy was associated with a significantly reduced risk of cardiac mortality in patients with diabetes mellitus and coronary artery disease after complete revascularization.

MeSH terms

  • Coronary Artery Disease / drug therapy*
  • Coronary Artery Disease / etiology*
  • Coronary Artery Disease / surgery
  • Diabetes Complications / drug therapy*
  • Diabetes Complications / pathology
  • Diabetes Mellitus / drug therapy*
  • Diabetes Mellitus / pathology
  • Female
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Male
  • Middle Aged
  • Myocardial Revascularization*
  • Pravastatin / therapeutic use*
  • Risk Factors
  • Survival Rate
  • Treatment Outcome

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Pravastatin